Risk  ||| S:0 E:5 ||| NN
factors  ||| S:5 E:13 ||| NNS
for  ||| S:13 E:17 ||| IN
graft  ||| S:17 E:23 ||| JJ
loss  ||| S:23 E:28 ||| NN
and  ||| S:28 E:32 ||| CC
mortality  ||| S:32 E:42 ||| NN
after  ||| S:42 E:48 ||| IN
renal  ||| S:48 E:54 ||| JJ
transplantation  ||| S:54 E:70 ||| NN
according  ||| S:70 E:80 ||| VBG
to  ||| S:80 E:83 ||| TO
recipient  ||| S:83 E:93 ||| JJ
age ||| S:93 E:96 ||| NN
:  ||| S:96 E:98 ||| :
a  ||| S:98 E:100 ||| DT
prospective  ||| S:100 E:112 ||| JJ
multicentre  ||| S:112 E:124 ||| JJ
study  ||| S:124 E:130 ||| NN
To  ||| S:130 E:133 ||| TO
describe  ||| S:133 E:142 ||| VB
the  ||| S:142 E:146 ||| DT
causes  ||| S:146 E:153 ||| NNS
of  ||| S:153 E:156 ||| IN
graft  ||| S:156 E:162 ||| JJ
loss ||| S:162 E:166 ||| NN
,  ||| S:166 E:168 ||| ,
patient  ||| S:168 E:176 ||| JJ
death  ||| S:176 E:182 ||| NN
and  ||| S:182 E:186 ||| CC
survival  ||| S:186 E:195 ||| NN
figures  ||| S:195 E:203 ||| NNS
in  ||| S:203 E:206 ||| IN
kidney  ||| S:206 E:213 ||| NN
transplant  ||| S:213 E:224 ||| NN
patients  ||| S:224 E:233 ||| NNS
in  ||| S:233 E:236 ||| IN
Spain  ||| S:236 E:242 ||| NNP
based  ||| S:242 E:248 ||| VBN
on  ||| S:248 E:251 ||| IN
the  ||| S:251 E:255 ||| DT
recipient ||| S:255 E:264 ||| NN
's  ||| S:264 E:267 ||| POS
age ||| S:267 E:270 ||| NN
.  ||| S:270 E:272 ||| .
The  ||| S:272 E:276 ||| DT
results  ||| S:276 E:284 ||| NNS
at  ||| S:284 E:287 ||| IN
5  ||| S:287 E:289 ||| CD
years  ||| S:289 E:295 ||| NNS
of  ||| S:295 E:298 ||| IN
post-transplant  ||| S:298 E:314 ||| JJ
cardiovascular  ||| S:314 E:329 ||| JJ
disease  ||| S:329 E:337 ||| NN
( ||| S:337 E:338 ||| -LRB-
CVD ||| S:338 E:341 ||| NNP
)  ||| S:341 E:343 ||| -RRB-
patients ||| S:343 E:351 ||| NNS
,  ||| S:351 E:353 ||| ,
taken  ||| S:353 E:359 ||| VBN
from  ||| S:359 E:364 ||| IN
a  ||| S:364 E:366 ||| DT
database  ||| S:366 E:375 ||| NN
on  ||| S:375 E:378 ||| IN
CVD ||| S:378 E:381 ||| NNP
,  ||| S:381 E:383 ||| ,
were  ||| S:383 E:388 ||| VBD
prospectively  ||| S:388 E:402 ||| JJ
analysed ||| S:402 E:410 ||| NN
,  ||| S:410 E:412 ||| ,
i.e.  ||| S:412 E:417 ||| FW
a  ||| S:417 E:419 ||| DT
total  ||| S:419 E:425 ||| NN
of  ||| S:425 E:428 ||| IN
2600  ||| S:428 E:433 ||| CD
transplanted  ||| S:433 E:446 ||| CD
patients  ||| S:446 E:455 ||| NNS
during  ||| S:455 E:462 ||| IN
2000-2002  ||| S:462 E:472 ||| CD
in  ||| S:472 E:475 ||| IN
14  ||| S:475 E:478 ||| CD
Spanish  ||| S:478 E:486 ||| JJ
renal  ||| S:486 E:492 ||| JJ
transplant  ||| S:492 E:503 ||| NN
units ||| S:503 E:508 ||| NNS
,  ||| S:508 E:510 ||| ,
most  ||| S:510 E:515 ||| JJS
of  ||| S:515 E:518 ||| IN
them  ||| S:518 E:523 ||| PRP
receiving  ||| S:523 E:533 ||| VBG
their  ||| S:533 E:539 ||| PRP$
organ  ||| S:539 E:545 ||| NN
from  ||| S:545 E:550 ||| IN
cadaver  ||| S:550 E:558 ||| JJ
donors ||| S:558 E:564 ||| NNS
.  ||| S:564 E:566 ||| .
Patients  ||| S:566 E:575 ||| NNS
were  ||| S:575 E:580 ||| VBD
grouped  ||| S:580 E:588 ||| VBN
according  ||| S:588 E:598 ||| VBG
to  ||| S:598 E:601 ||| TO
the  ||| S:601 E:605 ||| DT
recipient ||| S:605 E:614 ||| NN
's  ||| S:614 E:617 ||| POS
age ||| S:617 E:620 ||| NN
:  ||| S:620 E:622 ||| :
Group  ||| S:622 E:628 ||| NNP
A ||| S:628 E:629 ||| NNP
:  ||| S:629 E:631 ||| :
< ||| S:631 E:632 ||| SYM
40  ||| S:632 E:635 ||| CD
years ||| S:635 E:640 ||| NNS
,  ||| S:640 E:642 ||| ,
Group  ||| S:642 E:648 ||| NNP
B ||| S:648 E:649 ||| NNP
:  ||| S:649 E:651 ||| :
40-60  ||| S:651 E:657 ||| CD
years  ||| S:657 E:663 ||| NNS
and  ||| S:663 E:667 ||| CC
Group  ||| S:667 E:673 ||| NNP
C ||| S:673 E:674 ||| NNP
:  ||| S:674 E:676 ||| :
> ||| S:676 E:677 ||| CD
60  ||| S:677 E:680 ||| CD
years ||| S:680 E:685 ||| NNS
.  ||| S:685 E:687 ||| .
The  ||| S:687 E:691 ||| DT
most  ||| S:691 E:696 ||| RBS
frequent  ||| S:696 E:705 ||| JJ
immunosuppressive  ||| S:705 E:723 ||| JJ
regimen  ||| S:723 E:731 ||| NN
included  ||| S:731 E:740 ||| VBD
tacrolimus ||| S:740 E:750 ||| CD
,  ||| S:750 E:752 ||| ,
mycophenolate  ||| S:752 E:766 ||| JJ
mofetil  ||| S:766 E:774 ||| NN
and  ||| S:774 E:778 ||| CC
steroids ||| S:778 E:786 ||| NNS
.  ||| S:786 E:788 ||| .
Patients  ||| S:788 E:797 ||| NNS
were  ||| S:797 E:802 ||| VBD
distributed  ||| S:802 E:814 ||| VBN
as  ||| S:814 E:817 ||| RB
follows ||| S:817 E:824 ||| VBZ
:  ||| S:824 E:826 ||| :
25.85 ||| S:826 E:831 ||| CD
%  ||| S:831 E:833 ||| NN
in  ||| S:833 E:836 ||| IN
Group  ||| S:836 E:842 ||| NNP
A  ||| S:842 E:844 ||| NNP
( ||| S:844 E:845 ||| -LRB-
> ||| S:845 E:846 ||| CD
40  ||| S:846 E:849 ||| CD
years ||| S:849 E:854 ||| NNS
) ||| S:854 E:855 ||| -RRB-
,  ||| S:855 E:857 ||| ,
50.9 ||| S:857 E:861 ||| CD
%  ||| S:861 E:863 ||| NN
in  ||| S:863 E:866 ||| IN
Group  ||| S:866 E:872 ||| NNP
B  ||| S:872 E:874 ||| NNP
( ||| S:874 E:875 ||| -LRB-
40-60  ||| S:875 E:881 ||| CD
years ||| S:881 E:886 ||| NNS
)  ||| S:886 E:888 ||| -RRB-
and  ||| S:888 E:892 ||| CC
23.19 ||| S:892 E:897 ||| CD
%  ||| S:897 E:899 ||| NN
in  ||| S:899 E:902 ||| IN
Group  ||| S:902 E:908 ||| NNP
C  ||| S:908 E:910 ||| NNP
( ||| S:910 E:911 ||| -LRB-
> ||| S:911 E:912 ||| CD
60 ||| S:912 E:914 ||| CD
) ||| S:914 E:915 ||| -RRB-
.  ||| S:915 E:917 ||| .
The  ||| S:917 E:921 ||| DT
5-year  ||| S:921 E:928 ||| JJ
survival  ||| S:928 E:937 ||| NN
for  ||| S:937 E:941 ||| IN
the  ||| S:941 E:945 ||| DT
different  ||| S:945 E:955 ||| JJ
age  ||| S:955 E:959 ||| NN
groups  ||| S:959 E:966 ||| NNS
was  ||| S:966 E:970 ||| VBD
97.4 ||| S:970 E:974 ||| CD
,  ||| S:974 E:976 ||| ,
90.8  ||| S:976 E:981 ||| NNP
and  ||| S:981 E:985 ||| CC
77.7 ||| S:985 E:989 ||| CD
% ||| S:989 E:990 ||| NN
,  ||| S:990 E:992 ||| ,
respectively ||| S:992 E:1004 ||| RB
.  ||| S:1004 E:1006 ||| .
Death-censored  ||| S:1006 E:1021 ||| JJ
graft  ||| S:1021 E:1027 ||| JJ
survival  ||| S:1027 E:1036 ||| NN
was  ||| S:1036 E:1040 ||| VBD
88 ||| S:1040 E:1042 ||| CD
,  ||| S:1042 E:1044 ||| ,
84.2  ||| S:1044 E:1049 ||| NNP
and  ||| S:1049 E:1053 ||| CC
79.1 ||| S:1053 E:1057 ||| CD
% ||| S:1057 E:1058 ||| NN
,  ||| S:1058 E:1060 ||| ,
respectively ||| S:1060 E:1072 ||| RB
,  ||| S:1072 E:1074 ||| ,
and  ||| S:1074 E:1078 ||| CC
non  ||| S:1078 E:1082 ||| JJ
death-censored  ||| S:1082 E:1097 ||| JJ
graft  ||| S:1097 E:1103 ||| JJ
survival  ||| S:1103 E:1112 ||| NN
was  ||| S:1112 E:1116 ||| VBD
82.1 ||| S:1116 E:1120 ||| CD
,  ||| S:1120 E:1122 ||| ,
80.3  ||| S:1122 E:1127 ||| NNP
and  ||| S:1127 E:1131 ||| CC
64.7 ||| S:1131 E:1135 ||| CD
% ||| S:1135 E:1136 ||| NN
,  ||| S:1136 E:1138 ||| ,
respectively ||| S:1138 E:1150 ||| RB
.  ||| S:1150 E:1152 ||| .
Across  ||| S:1152 E:1159 ||| IN
all  ||| S:1159 E:1163 ||| DT
age  ||| S:1163 E:1167 ||| NN
groups ||| S:1167 E:1173 ||| NNS
,  ||| S:1173 E:1175 ||| ,
CVD  ||| S:1175 E:1179 ||| NNP
and  ||| S:1179 E:1183 ||| CC
infections  ||| S:1183 E:1194 ||| NNS
were  ||| S:1194 E:1199 ||| VBD
the  ||| S:1199 E:1203 ||| DT
most  ||| S:1203 E:1208 ||| RBS
frequent  ||| S:1208 E:1217 ||| JJ
cause  ||| S:1217 E:1223 ||| NN
of  ||| S:1223 E:1226 ||| IN
death ||| S:1226 E:1231 ||| NN
.  ||| S:1231 E:1233 ||| .
The  ||| S:1233 E:1237 ||| DT
main  ||| S:1237 E:1242 ||| JJ
causes  ||| S:1242 E:1249 ||| NNS
of  ||| S:1249 E:1252 ||| IN
graft  ||| S:1252 E:1258 ||| JJ
loss  ||| S:1258 E:1263 ||| NN
were  ||| S:1263 E:1268 ||| VBD
chronic  ||| S:1268 E:1276 ||| JJ
allograft  ||| S:1276 E:1286 ||| JJ
dysfunction  ||| S:1286 E:1298 ||| NN
in  ||| S:1298 E:1301 ||| IN
patients  ||| S:1301 E:1310 ||| NNS
< ||| S:1310 E:1311 ||| SYM
40  ||| S:1311 E:1314 ||| CD
years  ||| S:1314 E:1320 ||| NNS
old  ||| S:1320 E:1324 ||| JJ
and  ||| S:1324 E:1328 ||| CC
death  ||| S:1328 E:1334 ||| NN
with  ||| S:1334 E:1339 ||| IN
functioning  ||| S:1339 E:1351 ||| VBG
graft  ||| S:1351 E:1357 ||| NN
in  ||| S:1357 E:1360 ||| IN
the  ||| S:1360 E:1364 ||| DT
two  ||| S:1364 E:1368 ||| CD
remaining  ||| S:1368 E:1378 ||| JJ
groups ||| S:1378 E:1384 ||| NNS
.  ||| S:1384 E:1386 ||| .
In  ||| S:1386 E:1389 ||| IN
the  ||| S:1389 E:1393 ||| DT
multivariate  ||| S:1393 E:1406 ||| JJ
analysis  ||| S:1406 E:1415 ||| NN
for  ||| S:1415 E:1419 ||| IN
graft  ||| S:1419 E:1425 ||| JJ
survival ||| S:1425 E:1433 ||| NN
,  ||| S:1433 E:1435 ||| ,
only  ||| S:1435 E:1440 ||| RB
elevated  ||| S:1440 E:1449 ||| VBD
creatinine  ||| S:1449 E:1460 ||| JJ
levels  ||| S:1460 E:1467 ||| NNS
and  ||| S:1467 E:1471 ||| CC
proteinuria  ||| S:1471 E:1483 ||| CD
> ||| S:1483 E:1484 ||| CD
1  ||| S:1484 E:1486 ||| CD
g  ||| S:1486 E:1488 ||| NN
at  ||| S:1488 E:1491 ||| IN
6  ||| S:1491 E:1493 ||| CD
months  ||| S:1493 E:1500 ||| NNS
post-transplantation  ||| S:1500 E:1521 ||| NN
were  ||| S:1521 E:1526 ||| VBD
statistically  ||| S:1526 E:1540 ||| RB
significant  ||| S:1540 E:1552 ||| JJ
in  ||| S:1552 E:1555 ||| IN
the  ||| S:1555 E:1559 ||| DT
three  ||| S:1559 E:1565 ||| CD
age  ||| S:1565 E:1569 ||| NN
groups ||| S:1569 E:1575 ||| NNS
.  ||| S:1575 E:1577 ||| .
The  ||| S:1577 E:1581 ||| DT
patient  ||| S:1581 E:1589 ||| JJ
survival  ||| S:1589 E:1598 ||| NN
multivariate  ||| S:1598 E:1611 ||| NN
analysis  ||| S:1611 E:1620 ||| NN
did  ||| S:1620 E:1624 ||| VBD
not  ||| S:1624 E:1628 ||| RB
achieve  ||| S:1628 E:1636 ||| VB
a  ||| S:1636 E:1638 ||| DT
statistically  ||| S:1638 E:1652 ||| JJ
significant  ||| S:1652 E:1664 ||| JJ
common  ||| S:1664 E:1671 ||| JJ
factor  ||| S:1671 E:1678 ||| NN
in  ||| S:1678 E:1681 ||| IN
the  ||| S:1681 E:1685 ||| DT
three  ||| S:1685 E:1691 ||| CD
age  ||| S:1691 E:1695 ||| NN
groups ||| S:1695 E:1701 ||| NNS
.  ||| S:1701 E:1703 ||| .
Five-year  ||| S:1703 E:1713 ||| JJ
results  ||| S:1713 E:1721 ||| NNS
show  ||| S:1721 E:1726 ||| VBP
an  ||| S:1726 E:1729 ||| DT
excellent  ||| S:1729 E:1739 ||| JJ
recipient  ||| S:1739 E:1749 ||| JJ
survival  ||| S:1749 E:1758 ||| NN
and  ||| S:1758 E:1762 ||| CC
graft  ||| S:1762 E:1768 ||| JJ
survival ||| S:1768 E:1776 ||| NN
,  ||| S:1776 E:1778 ||| ,
especially  ||| S:1778 E:1789 ||| RB
in  ||| S:1789 E:1792 ||| IN
the  ||| S:1792 E:1796 ||| DT
youngest  ||| S:1796 E:1805 ||| JJS
age  ||| S:1805 E:1809 ||| NN
group ||| S:1809 E:1814 ||| NN
.  ||| S:1814 E:1816 ||| .
Death  ||| S:1816 E:1822 ||| NN
with  ||| S:1822 E:1827 ||| IN
functioning  ||| S:1827 E:1839 ||| VBG
graft  ||| S:1839 E:1845 ||| NN
is  ||| S:1845 E:1848 ||| VBZ
the  ||| S:1848 E:1852 ||| DT
leading  ||| S:1852 E:1860 ||| JJ
cause  ||| S:1860 E:1866 ||| NN
of  ||| S:1866 E:1869 ||| IN
graft  ||| S:1869 E:1875 ||| JJ
loss  ||| S:1875 E:1880 ||| NN
in  ||| S:1880 E:1883 ||| IN
patients  ||| S:1883 E:1892 ||| NNS
> ||| S:1892 E:1893 ||| CD
40  ||| S:1893 E:1896 ||| CD
years ||| S:1896 E:1901 ||| NNS
.  ||| S:1901 E:1903 ||| .
Early  ||| S:1903 E:1909 ||| JJ
improvement  ||| S:1909 E:1921 ||| NN
of  ||| S:1921 E:1924 ||| IN
renal  ||| S:1924 E:1930 ||| JJ
function  ||| S:1930 E:1939 ||| NN
and  ||| S:1939 E:1943 ||| CC
proteinuria  ||| S:1943 E:1955 ||| VBG
together  ||| S:1955 E:1964 ||| RP
with  ||| S:1964 E:1969 ||| IN
strict  ||| S:1969 E:1976 ||| JJ
control  ||| S:1976 E:1984 ||| NN
of  ||| S:1984 E:1987 ||| IN
cardiovascular  ||| S:1987 E:2002 ||| JJ
risk  ||| S:2002 E:2007 ||| NN
factors  ||| S:2007 E:2015 ||| NNS
are  ||| S:2015 E:2019 ||| VBP
mandatory ||| S:2019 E:2028 ||| JJ
.  ||| S:2028 E:2030 ||| .
